A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 8, Pages 1743-1751
Publisher
Springer Nature
Online
2016-12-27
DOI
10.1038/leu.2016.388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Blinatumomab: First Global Approval
- (2015) Mark Sanford DRUGS
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma
- (2015) Antonio Palumbo et al. Expert Review of Hematology
- Chemokine Receptor Expression on Normal Blood CD56+NK-Cells Elucidates Cell Partners That Comigrate during the Innate and Adaptive Immune Responses and Identifies a Transitional NK-Cell Population
- (2015) Margarida Lima et al. Journal of Immunology Research
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
- (2014) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
- (2010) J. Quinn et al. BLOOD
- The immortality of humoral immunity
- (2010) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
- (2010) Stephanie Markovina et al. Molecular Cancer
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now